What a Peptide Synthesis Company Actually Does

By Sciences Peptides Editorial Team · Lab-reviewed 2026-09-13 · Evidence-graded per our editorial policy

Synthesis service versus reselling

A genuine peptide synthesis company manufactures: it takes a sequence specification, quotes a price from length and difficulty, synthesizes by SPPS, purifies by preparative HPLC, verifies each batch analytically, and ships the batch documents with the material. A reseller buys synthesized material wholesale and vials it. The distinction is invisible in a product listing and completely visible in the paperwork — which is why our company profiles, like precision peptide company, read the documents first.

The commercial shapes differ predictably. Synthesis houses quote per project with prices scaling by milligram, purity spec, and sequence difficulty (length, aggregation-prone residues, cysteine content, modifications like phosphorylation). Resellers publish flat catalogs at fixed vial prices. Neither model is illegitimate; but buyers comparing a custom-synthesis quote against a catalog price per milligram are usually comparing two different quality levels, not two prices for one product — a trap our peptide price page untangles.

What a synthesis contract should produce

A professional synthesis order ends with a defined document set: batch COA with lot number; analytical HPLC chromatogram with method and wavelength; LC-MS identity confirmation; net content determination (typically by elemental nitrogen or weight comparison against a calibrated standard); and residual-solvent statement where relevant. Missing any of these, the "synthesis service" was a vialing operation with a chemistry vocabulary.

Tier differences are real here. At the top, GMP CDMOs like Bachem run validated methods under regulatory inspection for drug-company clients. Below them, custom-synthesis houses run research-grade (non-GMP) processes with honest per-batch QC. The gray market's "synthesized in-house" claims occupy a third, undocumented position. Our top peptide companies pillar maps the whole ladder; this page is about how to read whichever rung you are standing on.

What actually drives difficulty and price

Sequence length is the visible driver, but the invisible ones set the price: hydrophobic stretches and aggregation tendency (beta-sheet-prone sequences purify badly and re-dissolve worse); cysteine count (disulfide isomer management); terminal modifications (acetylation, amidation, conjugations); and isotope or fluorescent labels, which multiply cost. A 40-mer with three disulfides is a project; the same residues as a linear 10-mer are a commodity — which is why per-milligram price comparisons without sequence context are noise.

For research buyers, the practical synthesis-company questions are: do they publish per-batch QC for catalog items; do they quote purification tier and yield honestly; and do they disclose the analysis method. Those three behaviors predict everything else about the working relationship. The full quality checklist lives in best quality peptides, and the science behind the QC numbers lives in our root pillar, peptide science.

How to use the data on this page

Step 1 — extract the parameters. Start with the claims made about What a Peptide Synthesis Company Actually Does and write down every number you can find: purity, net content, fill mass, salt form, and the analytical method named. Numbers that do not appear are as important as numbers that do; the gap list is your first finding. Step 2 — normalize before comparing. Convert every figure to the same basis: per milligram of net peptide content, at the stated lot purity, in the stated salt form. The comparison table above shows which parameters move the answer most; net content alone typically shifts effective figures by 15–30%. Step 3 — grade the source. A batch-linked COA outranks a representative chromatogram, which outranks a marketing claim with no artifact behind it. When two sources conflict, trust the more specific, more recent, more checkable one — and note the conflict rather than averaging it away. The full evidence hierarchy is defined in the peptide science pillar; a worked example on a neighboring topic is on High Purity Peptides.

Parameter comparison: how the quality numbers differ

The parameters below are the ones every peptide buyer or laboratory should be able to read off a certificate of analysis. Compare what each parameter measures, what honest values look like, and what a red flag looks like, before using any vendor's figures.

ParameterWhat it measuresTypical documented rangeRed flag
Purity (HPLC area %)Main peak as a share of all UV-absorbing species95.0–99.5% stated per lot"≥98%" with no method, lot, or wavelength
Net contentFraction of vial mass that is actual peptide70–85% for TFA saltsGross fill quoted as if it were peptide mass
Salt formCounter-ion bound to the peptide (TFA, acetate, chloride)Stated explicitly; acetate for pharmacology workNever mentioned at all
MS identityMolecular weight confirmation by mass spectrometryReported with calculated and found massAbsent; HPLC retention time presented as identity
Fill accuracyAgreement of vial mass with the labelWithin analytical tolerance, reweighableSystematically under; no reweigh data published
Storage & retest dateStated conditions and shelf life for the lot−20°C, desiccated, datedNo storage or dating information on the COA

Table: Parameter comparison: how the quality numbers differ — apply it to any page in this cluster.

Frequently asked questions

What does a peptide synthesis company provide that a vendor doesn't?
Manufacturing control: project quoting, method development, per-batch analytical QC (HPLC, LC-MS, net content), and the document set that comes with it. Resellers vial material; synthesis companies produce it.
Why do synthesis quotes vary so much for the same sequence?
Price scales with length, purity spec, and difficulty — aggregation-prone stretches, disulfide management, terminal modifications, labels. Two quotes for 'the same peptide' often specify different purity tiers or QC depth.

References

  1. Chan WC, White PD. Fmoc Solid Phase Peptide Synthesis. Oxford University Press; 2000.
  2. Bachem annual reports and service documentation (public filings).